Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting

NCT05266495 · clinicaltrials.gov ↗

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Stopped Company Decision

Conditions

Neovascular Age-related Macular Degeneration

Interventions

OTHER: Brolucizumab

Sponsor

Novartis Pharmaceuticals